Medication-Assisted Treatment Explained
A comprehensive guide to FDA-approved medications for addiction, how they work, who they help, and why MAT is one of the most effective evidence-based approaches to recovery.
Understanding Medication-Assisted Treatment
Medication-Assisted Treatment, commonly known as MAT, is an evidence-based approach to addiction treatment that combines FDA-approved medications with counseling and behavioral therapies to provide a comprehensive, whole-patient approach to substance use disorders. MAT has been proven to be one of the most effective strategies available for treating opioid use disorder and alcohol use disorder, significantly improving treatment outcomes, reducing relapse rates, decreasing overdose deaths, and supporting long-term recovery. Despite its strong evidence base and endorsement by virtually every major medical and public health organization, MAT remains underutilized and widely misunderstood. Misconceptions that MAT simply replaces one addiction with another, that it represents a crutch rather than true recovery, or that people using MAT are not really sober have prevented countless individuals from accessing treatment that could save their lives. These myths are not supported by science. MAT medications work by normalizing brain chemistry, blocking the euphoric effects of addictive substances, relieving physiological cravings, and stabilizing body functions — without producing the high, impairment, or destructive behaviors associated with the substance of abuse. The Substance Abuse and Mental Health Services Administration, the National Institute on Drug Abuse, the World Health Organization, and the American Society of Addiction Medicine all endorse MAT as a first-line treatment for opioid and alcohol use disorders. This guide will help you understand what MAT is, how each approved medication works, who is a candidate for MAT, how to access treatment, and how MAT integrates with counseling, peer support, and recovery tools like the Sobrius app to create a comprehensive recovery plan. If you or someone you love is struggling with addiction, understanding MAT may open doors to treatment options you did not know existed.
What Is MAT and How Does It Work?
Medication-Assisted Treatment is a clinical approach that uses pharmaceutical medications in combination with psychological counseling and behavioral therapies to treat substance use disorders. The "medication" component addresses the biological dimension of addiction — the neurochemical changes in the brain that drive cravings, withdrawal symptoms, and compulsive use — while the "counseling" component addresses the psychological, social, and behavioral dimensions. Neither component alone is as effective as the combination, which is why the integrated approach is considered the gold standard. MAT works through several pharmacological mechanisms depending on the specific medication used. Agonist medications like methadone and buprenorphine activate the same opioid receptors as drugs of abuse but in a controlled, medically supervised manner that prevents withdrawal symptoms and reduces cravings without producing the dangerous high associated with illicit opioid use. These medications stabilize the brain's opioid system, allowing the person to function normally, engage in therapy, maintain employment, and rebuild their life while their brain gradually heals from the effects of chronic drug exposure. Antagonist medications like naltrexone work by blocking opioid receptors entirely, preventing any opioid from producing euphoric effects. If a person taking naltrexone uses an opioid, they will not experience the rewarding high, which eliminates the reinforcement that drives continued use. This mechanism is particularly effective for highly motivated individuals who want an additional safeguard against relapse. For alcohol use disorder, medications work through different but equally important mechanisms. Naltrexone reduces the pleasurable effects of alcohol and diminishes cravings. Acamprosate helps restore the balance of neurotransmitter systems disrupted by chronic alcohol use, reducing the persistent discomfort and anxiety that often drive relapse. Disulfiram creates an intensely unpleasant physical reaction when alcohol is consumed, providing a powerful deterrent. The counseling component of MAT typically includes individual therapy, group therapy, and support services. Cognitive-behavioral therapy helps patients identify and change thought patterns and behaviors that contribute to substance use. Motivational interviewing builds and strengthens internal motivation for change. Contingency management provides tangible rewards for maintaining abstinence and treatment adherence. Family therapy addresses relationship dynamics that may contribute to or be affected by addiction. Together, these therapeutic approaches address the full complexity of addiction in ways that medication alone cannot.
Agonist Medications
Methadone and buprenorphine activate opioid receptors in a controlled manner, preventing withdrawal and cravings without producing dangerous euphoria, allowing normal daily functioning during recovery.
Antagonist Medications
Naltrexone blocks opioid receptors entirely, preventing any opioid from producing rewarding effects and eliminating the reinforcement cycle that drives continued use and relapse.
Alcohol-Specific Medications
Naltrexone reduces alcohol pleasure and cravings, acamprosate restores disrupted neurotransmitter balance, and disulfiram creates aversive reactions to alcohol consumption as a relapse deterrent.
Integrated Counseling
CBT, motivational interviewing, contingency management, and family therapy address the psychological and behavioral dimensions of addiction that medication alone cannot resolve.
FDA-Approved Medications for Addiction
Several medications have received FDA approval for treating opioid and alcohol use disorders, each with distinct mechanisms of action, administration methods, and clinical profiles. Understanding these options helps patients and families make informed decisions in partnership with their healthcare providers. Naltrexone is approved for both opioid and alcohol use disorders. For opioid addiction, it is available as a daily oral tablet (ReVia) or a monthly extended-release intramuscular injection (Vivitrol). The injectable form is particularly valuable because it eliminates the need for daily medication adherence, which is a common barrier to treatment success. Naltrexone works by completely blocking opioid receptors, so if a person uses opioids while taking naltrexone, they will experience no euphoric effects. For alcohol use disorder, naltrexone reduces the pleasurable effects of drinking and decreases cravings, making it easier for individuals to maintain abstinence or significantly reduce their consumption. Clinical trials have shown that naltrexone reduces heavy drinking days by approximately thirty-six percent and increases abstinence rates compared to placebo. Buprenorphine, marketed under brand names including Suboxone, Sublocade, and Zubsolv, is a partial opioid agonist approved for opioid use disorder. As a partial agonist, it activates opioid receptors enough to prevent withdrawal symptoms and reduce cravings but has a ceiling effect that limits its euphoric potential, making it significantly safer than full agonist opioids. Suboxone combines buprenorphine with naloxone to deter misuse — if the medication is injected rather than taken sublingually as directed, the naloxone component triggers immediate withdrawal. Buprenorphine can be prescribed in office-based settings by qualified physicians, making it more accessible than methadone. Methadone is a full opioid agonist that has been used to treat opioid addiction since the 1960s. It is the oldest and most extensively studied MAT medication, with decades of evidence supporting its effectiveness. Methadone is dispensed through specially licensed opioid treatment programs (OTPs) and requires daily supervised dosing, at least initially, which provides structure but also creates accessibility barriers for some patients. When properly dosed, methadone eliminates withdrawal symptoms, suppresses cravings, and blocks the effects of other opioids without producing the euphoric high associated with heroin or prescription opioid misuse. Acamprosate (Campral) is approved for maintaining abstinence in patients with alcohol use disorder who have already achieved initial sobriety. It works by modulating the glutamate and GABA neurotransmitter systems that become disrupted during chronic alcohol use, reducing the persistent anxiety, insomnia, and dysphoria that often trigger relapse. Acamprosate is taken three times daily and is generally well-tolerated. Disulfiram (Antabuse) is the oldest approved medication for alcohol use disorder. It works through a deterrent mechanism — it inhibits the enzyme aldehyde dehydrogenase, causing an accumulation of acetaldehyde when alcohol is consumed. This produces intensely unpleasant symptoms including flushing, nausea, vomiting, headache, and rapid heartbeat. The effectiveness of disulfiram depends on consistent daily compliance, as it only works if the person takes it before drinking.
Naltrexone / Vivitrol
An opioid antagonist available as daily oral tablets or monthly injection, approved for both opioid and alcohol use disorders, blocking euphoric effects and reducing cravings for either substance.
Buprenorphine / Suboxone
A partial opioid agonist with ceiling effect that prevents withdrawal and cravings while limiting abuse potential, prescribable in office settings for greater accessibility than methadone.
Methadone
A full opioid agonist dispensed through licensed treatment programs that eliminates withdrawal, suppresses cravings, and blocks other opioid effects, supported by over sixty years of clinical evidence.
Acamprosate and Disulfiram
Acamprosate restores neurotransmitter balance disrupted by chronic alcohol use, while disulfiram creates aversive physical reactions to alcohol consumption as a compliance-dependent relapse deterrent.
Support your MAT journey with Sobrius
Track your recovery milestones, stay motivated between appointments, and build a visible record of your progress — one day at a time.
Myths vs. Facts About MAT
Despite decades of evidence supporting its effectiveness, Medication-Assisted Treatment remains surrounded by misconceptions that prevent many people from accessing life-saving care. Addressing these myths directly is essential for reducing stigma and helping individuals make informed decisions about their treatment. Myth: MAT just replaces one addiction with another. Fact: This is the most pervasive and harmful misconception about MAT. Addiction is characterized by compulsive use despite negative consequences, impaired control, and progressive deterioration of functioning. MAT medications, when taken as prescribed, produce none of these features. They normalize brain chemistry, reduce cravings, and prevent withdrawal without creating impairment, euphoria, or destructive behavior. A person stabilized on buprenorphine or methadone can work, maintain relationships, drive safely, and function normally in every aspect of life. This is fundamentally different from active addiction. The analogy is insulin for diabetes — treating a chronic brain condition with appropriate medication is not substituting one disease for another. Myth: People on MAT are not truly sober. Fact: This belief, which is unfortunately perpetuated in some recovery communities, causes real harm by stigmatizing an evidence-based treatment and discouraging people from using it. Sobriety encompasses the restoration of health, functioning, and quality of life that addiction destroyed. MAT supports exactly this restoration. The Substance Abuse and Mental Health Services Administration explicitly states that MAT patients are considered to be in recovery. The exclusion of MAT patients from certain recovery communities or housing programs based on the belief that they are not sober contradicts medical science and can have fatal consequences. Myth: MAT should only be used short-term. Fact: While some individuals may eventually taper off MAT medications, research consistently shows that longer durations of MAT are associated with better outcomes. Discontinuing MAT prematurely is one of the strongest predictors of relapse and, in the case of opioid use disorder, overdose death. The optimal duration of MAT varies by individual and should be determined collaboratively between the patient and their healthcare provider based on clinical response, not arbitrary timelines. For some individuals, long-term or indefinite maintenance is the most appropriate and evidence-supported approach. Myth: MAT is only for severe addiction. Fact: MAT can be beneficial at various stages of substance use disorder severity. Early intervention with MAT can prevent the progression to more severe addiction and reduce the cumulative damage to health, relationships, and careers. There is no requirement that a person reach a certain level of severity before MAT becomes appropriate. Myth: MAT medications are easy to abuse. Fact: MAT medications are specifically formulated and administered to minimize abuse potential. Buprenorphine has a ceiling effect that limits euphoria, and Suboxone includes naloxone to deter injection. Naltrexone produces no euphoria whatsoever. Methadone is dispensed under direct supervision. While no medication is completely immune to misuse, the controlled conditions of MAT vastly reduce this risk compared to continued illicit substance use.
Who Is a Candidate for MAT?
MAT is appropriate for a wide range of individuals with opioid or alcohol use disorders, and the criteria for candidacy are more inclusive than many people assume. In general, anyone who has been diagnosed with an opioid use disorder or alcohol use disorder and has not responded adequately to behavioral treatment alone may benefit from MAT. For opioid use disorder, MAT is considered the standard of care by major medical organizations. The American Society of Addiction Medicine recommends that all patients with opioid use disorder be offered MAT as a first-line treatment, not as a last resort after other approaches have failed. Candidates include individuals currently using illicit opioids such as heroin or fentanyl, those misusing prescription opioid pain medications, people who have previously attempted abstinence-based treatment and relapsed, individuals at high risk for overdose, and pregnant women with opioid use disorder, for whom MAT with buprenorphine or methadone is specifically recommended to protect both mother and developing child. For alcohol use disorder, MAT is appropriate for individuals who have difficulty maintaining abstinence through behavioral interventions alone, those who experience persistent cravings that threaten their sobriety, people in early recovery who need additional support while new coping mechanisms are being established, and those with moderate to severe alcohol use disorder as defined by DSM-5 criteria. The decision to begin MAT should be made collaboratively between the patient and a qualified healthcare provider, taking into account the individual's medical history, substance use history, previous treatment experiences, co-occurring mental and physical health conditions, personal preferences, and life circumstances. There are some contraindications for specific MAT medications. Naltrexone should not be initiated while a person still has opioids in their system, as it can precipitate acute withdrawal. Patients with severe liver disease may need modified dosing or alternative medications. Methadone requires careful dosing and monitoring due to its long half-life and potential for respiratory depression. Buprenorphine induction must be timed carefully to avoid precipitated withdrawal. These medical considerations underscore the importance of proper medical supervision when initiating MAT. It is also important to note that MAT is not limited to any particular demographic. People of all ages, backgrounds, professions, and addiction severities can benefit from MAT. The misconception that MAT is only for the most severely addicted or for those who have failed everything else is harmful and prevents many people from accessing effective treatment early in their disorder when outcomes are typically best.
Opioid Use Disorder
MAT is recommended as first-line treatment for all patients with opioid use disorder, including those using illicit opioids, misusing prescription medications, or at high risk for overdose.
Alcohol Use Disorder
MAT is appropriate for individuals who struggle with persistent cravings, difficulty maintaining abstinence through behavioral approaches alone, or moderate to severe alcohol use disorder.
Pregnant Individuals
MAT with buprenorphine or methadone is specifically recommended for pregnant women with opioid use disorder to protect both the mother and developing child from the risks of untreated addiction.
How to Access MAT and What to Expect
Accessing Medication-Assisted Treatment has become significantly easier in recent years as policy changes, telehealth expansion, and increased awareness have reduced many of the traditional barriers. However, navigating the system can still feel daunting, and understanding the process can help you take the first step with confidence. The most direct path to MAT is through your primary care physician. Following the elimination of the federal X-waiver requirement in 2023, any physician with a standard DEA registration can now prescribe buprenorphine for opioid use disorder without special certification. This policy change dramatically expanded access by allowing treatment to be integrated into routine medical care rather than requiring referral to specialized addiction programs. Simply calling your doctor and expressing interest in MAT for opioid or alcohol use disorder is a reasonable first step. If your primary care provider is not comfortable prescribing MAT medications, SAMHSA maintains an online treatment locator at findtreatment.gov that allows you to search for MAT providers by location. The SAMHSA National Helpline at 1-800-662-4357 can also connect you with local providers. Many addiction treatment centers now offer MAT as part of their programs, and an increasing number of community health centers and federally qualified health centers provide MAT services to underserved populations. Telehealth has become an important access point for MAT. Following regulatory changes that expanded during the COVID-19 pandemic, many MAT providers now offer initial evaluations and ongoing management via video or phone appointments. This is particularly valuable for individuals in rural areas, those with transportation barriers, or people whose work schedules make in-person appointments difficult. Once you connect with a MAT provider, the typical process begins with a comprehensive assessment that includes your substance use history, medical history, mental health evaluation, and discussion of treatment goals. Based on this assessment, the provider will recommend an appropriate medication and dosage. For buprenorphine, induction often occurs in the office or at home under phone guidance, and you will typically begin feeling relief from cravings and withdrawal within the first day. For naltrexone, you must be completely free of opioids for seven to fourteen days before starting to avoid precipitated withdrawal. For methadone, initial dosing occurs at a licensed OTP with daily visits that may gradually decrease in frequency as you stabilize. Regardless of which medication you receive, expect that counseling and behavioral therapy will be integrated into your treatment plan. This may include individual therapy sessions, group counseling, case management, and referrals to community support resources. Tracking your daily progress with the Sobrius app complements your MAT program by providing a personal record of your recovery journey, helping you celebrate milestones, and maintaining motivation between clinical appointments.
Finding a Provider
Any licensed physician can now prescribe buprenorphine. SAMHSA treatment locator at findtreatment.gov and the helpline at 1-800-662-4357 can connect you with local MAT providers.
Telehealth Options
Many MAT providers offer evaluations and ongoing management via video or phone appointments, expanding access for those in rural areas or with transportation or scheduling barriers.
Initial Assessment
The process begins with a comprehensive evaluation of your substance use, medical history, mental health, and treatment goals to determine the most appropriate medication and dosage.
Ongoing Integrated Care
MAT combines medication management with counseling, behavioral therapy, case management, and community support to address the full complexity of addiction and sustain long-term recovery.
Helpful Resources
SAMHSA Treatment Locator
Free, confidential online tool for finding MAT providers, treatment facilities, and support services by location, including filters for specific medications and treatment types.
1-800-662-4357
Visit WebsiteNational Institute on Drug Abuse (NIDA)
Comprehensive, research-based information on medication-assisted treatment, the science of addiction, and evidence-based treatment approaches for opioid and alcohol use disorders.
Visit WebsiteAmerican Society of Addiction Medicine (ASAM)
Professional organization providing clinical practice guidelines for MAT, a provider directory, and patient education resources on medication-assisted recovery.
Visit WebsiteProviders Clinical Support System (PCSS)
SAMHSA-funded resource offering training, clinical mentoring, and educational materials on evidence-based treatment of substance use disorders including MAT best practices.
Visit WebsiteFrequently Asked Questions
Find answers to common questions about recovery and sobriety.
Support your MAT journey with Sobrius
Track your recovery milestones, stay motivated between appointments, and build a visible record of your progress — one day at a time.